<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, the disclosure of ZIKV silent spread has underscored its latent threat to public health (
 <xref rid="B17" ref-type="bibr">Grubaugh et al., 2019</xref>). Considering there are still no approved vaccines, the development of specific drugs for ZIKV infection is paramount. The promising results observed in our present study suggest that ZY13, a representative analog of snake cathelicidin BF-30, is a promising molecule against ZIKV infection (summarized in 
 <xref ref-type="fig" rid="F6">Figure 6</xref>). Furthermore, our study also highlights the importance of venom peptides as prototypes for antivirals development.
</p>
